Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Pfizer Targets $100 Billion Weight Loss Market With New Drug

Published 07/12/2024, 08:56 PM
US500
-
LLY
-
PFE
-
NVO
-

Pharmaceutical giant Pfizer (NYSE:PFE) announced Thursday its decision to move forward with the development of a once-daily version of its weight loss pill, danuglipron, sparking a positive response from investors. The company’s stock rose 1.09% to $28.66 yesterday.

Pfizer’s Weight Loss Pill Development

Pfizer’s decision to continue developing danuglipron comes after “encouraging” data from an ongoing early-stage trial. The company identified a formulation with the most favorable safety profile and bodily reactions, paving the way for additional early-stage trials in the second half of 2024. Results from these trials are expected in the first quarter of 2025.

Dr. Mikael Dolsten, Pfizer’s outgoing Chief Scientific Officer, expressed confidence in the drug’s potential, stating that the once-daily formulation could be competitive in the oral GLP-1 agonist space. This class of drugs, which includes Novo Nordisk’s popular Wegovy and Ozempic, has seen soaring demand for weight loss and diabetes treatment.

The advancement of danuglipron represents a significant turnaround for Pfizer, which discontinued the twice-daily version of the drug in December due to tolerability issues.

Notably, no liver safety issues were observed in patients receiving the once-daily formulations, addressing a key concern that had previously hindered the company’s progress in this therapeutic area.

Pfizer’s Moment in the GLP-1 Market

This development keeps Pfizer in contention for a share of the projected $100 billion GLP-1 market, maintaining competitive pressure on market leaders Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE: NYSE:LLY).

It also signals Pfizer’s strategy to focus on internal development rather than late-stage acquisitions, though the company may still consider licensing deals or acquiring earlier-stage weight-loss drugs.

The news has implications for Pfizer’s financial outlook and stock performance. While the company’s stock is up 3.39% year-to-date, it has underperformed the S&P 500’s 18.14% gain.

Pfizer’s market capitalization stands at $163.702 billion, with a forward P/E ratio of 12.30 and a dividend yield of 5.43%. However, the company reported negative earnings per share of $0.05 over the trailing twelve months, reflecting recent challenges.

***

Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.

This article was originally published on The Tokenist. Check out The Tokenist’s free newsletter, Five Minute Finance, for weekly analysis of the biggest trends in finance and technology.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.